ライフサイエンスコーパス: angiotensin II type 1 receptor

1 n via derepression of its direct target gene angiotensin II type 1 receptor.

2 ptide-binding site of an activated GPCR, the angiotensin II type 1 receptor.

3 anges that are attenuated by blockade of the angiotensin II type 1 receptor.

4 ma membrane to facilitate endocytosis of the angiotensin II type 1 receptor.

5 o the carboxyl-terminal regulatory domain of angiotensin II type 1 receptors.

6 n gerbils expresses high amounts of atypical angiotensin II type-1 receptors.

7 We previously described angiotensin II type 1 receptor-activating antibodies (AT

8 omen, induced preproET-1 mRNA expression via angiotensin II type 1 receptor activation in kidneys and

9 We examined the in vivo function of the angiotensin II type 1 receptor (Agtr1) on macrophages in

10 (AGT), angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor (AGTR1), and aldosterone

11 Discoveries of biased ligands targeting the angiotensin II type 1 receptor and of separable pharmaco

12 track activation and internalization of the angiotensin II type 1 receptor and the beta2 adrenocepto

13 cells express abundant AT2 receptor but not angiotensin II type 1 receptor and undergo apoptosis whe

14 Isolated de novo anti-angiotensin II type-1 receptor and anti-endothelin-1 typ

15 0 to 4 of 2009 with known HLA DSA status for angiotensin II type-1 receptor and endothelin-1 type A r

16 f the renin-angiotensin system (RAS) with an angiotensin II type 1 receptor antagonist (AT1-ant) may

17 regression of existing glomerulosclerosis by angiotensin II type 1 receptor antagonist (AT1RA) and/or

18 Chronic administration of the angiotensin II type 1 receptor antagonist losartan to mu

19 aintained despite RVLM pretreatment with the angiotensin II type 1 receptor antagonist losartan, the

20 related with the therapeutic efficacy of the angiotensin II type 1 receptor antagonist losartan.

21 Treatment with an angiotensin II type 1 receptor antagonist normalized wat

22 We further show that the angiotensin II type 1 receptor antagonist, losartan, pre

23 Losartan (1 microM), an angiotensin II type 1 receptor antagonist, weakly inhibi

24 ntagonized by administration of losartan, an angiotensin II type 1 receptor antagonist.

25 ensin-converting enzyme inhibitors (ACEi) or angiotensin II type 1 receptor antagonists (AT(1)-ant),

26 cortex homogenate from patients treated with angiotensin II type 1 receptor antagonists (n=6) or angi

27 ted coupling while, in contrast to classical angiotensin II type 1 receptor antagonists, it engages b

28 tics of graft injury in the presence of anti-angiotensin II type 1 receptor antibody (AT1R-Ab) and an

29 ished that retrovirally mediated delivery of angiotensin II type 1 receptor antisense (AT1R-AS) atten

30 occurs selectively on neurons, and neuronal angiotensin II type 1 receptors are indispensable to thi

31 ction (MI) LV remodeling, but the effects of angiotensin II type 1 receptor (AT(1)) antagonism alone

32 Angiotensin II type 1 receptor (AT(1)R) is a G protein-c

33 have demonstrated that the expression of the angiotensin II type 1 receptor (AT(1)R) is regulated pre

34 ted cells and mouse hearts led us to examine angiotensin II type 1 receptor (AT(1)R)-dependent proteo

35 dies were used to identify ACE, macrophages, angiotensin II type 1 receptor (AT-1 receptor), angioten

36 ted against endothelin-1 type A (ET(A)R) and angiotensin II type 1 receptors (AT(1)R, cell-enzyme-lin

37 al cortex after angiotensin II activation of angiotensin II type 1 receptors (AT(1)Rs), G protein-cou

38 The Gq/11 protein-coupled angiotensin II type 1 receptor (AT1 R) has been shown to

39 Conversely, treatment with the angiotensin II type 1 receptor (AT1) antagonist candesar

40 onverting enzyme inhibitors and losartan, an angiotensin II type 1 receptor (AT1) antagonist, amelior

41 uch as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan.

42 dynamic change in the formation of an active angiotensin II type 1 receptor (AT1) dimer in GITR-L(-/-

43 The angiotensin II type 1 receptor (AT1) is a 7-transmembran

44 Blockade of the angiotensin II type 1 receptor (AT1) or stimulation of t

45 lates COX-2 expression via activation of the angiotensin II type 1 receptor (AT1) receptor.

46 enes for the ACE, angiotensinogen (AGT), and angiotensin II type 1 receptor (AT1).

47 Expression of the angiotensin II type 1 receptor (AT1-R) mRNA in vascular

48 or by concomitant treatment with a specific angiotensin II type-1 receptor (AT1) antagonist.

49 ts of G protein-independent signaling by the angiotensin II type 1 receptor (AT1R) (see the related a

50 e of regional myocardial upregulation of the angiotensin II type 1 receptor (AT1R) and the blocking e

51 Because the angiotensin II type 1 receptor (AT1R) and the multifunct

52 amined conformational changes in ECL2 of the angiotensin II type 1 receptor (AT1R) by introducing mut

53 To examine the relevance of angiotensin II type 1 receptor (AT1R) expression in the

54 te individuals, the A1166C 3'-UTR variant of angiotensin II type 1 receptor (AT1R) has been associate

55 e the feasibility of targeted imaging of the angiotensin II type 1 receptor (AT1R) in cardiac tissue,

56 The angiotensin II type 1 receptor (AT1R) in the central ner

57 The angiotensin II type 1 receptor (AT1R) is notable as it h

58 Angiotensin II type 1 receptor (AT1R) is the primary blo

59 kinase activities and marked upregulation of angiotensin II type 1 receptor (AT1R) mRNA and protein e

60 Pharmacological or genetic inhibition of angiotensin II type 1 receptor (AT1R) rescued the impair

61 It has recently been appreciated that the angiotensin II type 1 receptor (AT1R), a prototypic memb

62 The angiotensin II type 1 receptor (AT1R)-associated protein

63 se pathogenesis, mainly by its action on the angiotensin II type 1 receptor (AT1R).

64 d dissected out the contributory role of the angiotensin II Type 1 receptor (AT1R).

65 Drugs that block angiotensin II type 1 receptors (AT1R, encoded by AGTR1)

66 vities appear to involve cross-talk with the angiotensin II type-1 receptor (AT1R).

67 gnal-regulated kinase (ERK1/2) dependent and angiotensin-II type 1 receptor (AT1R) dependent.

68 t of alpha(2B)-adrenergic (alpha(2B)-AR) and angiotensin II type 1 receptors (AT1Rs) from the endopla

69 ween beta-adrenergic receptors (betaARs) and angiotensin II type 1 receptors (AT1Rs) has not been ide

70 Agonistic angiotensin II type 1 receptor autoantibodies (AT1RaAbs)

71 Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade have provided eq

72 angiotensin converting enzyme inhibition or angiotensin II type 1 receptor blockade incurs significa

73 The effect of angiotensin II type 1 receptor blockade with intracerebr

74 is study was to test the hypothesis that the angiotensin II type 1 receptor blocker (ARB) candesartan

75 nverting enzyme inhibitor (enalapril) and an angiotensin II type 1 receptor blocker (losartan) in thy

76 with the use of an ACE-I (captopril) and an angiotensin II type 1 receptor blocker (olmesartan).

77 ion of TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor blocker losartan normaliz

78 These effects were blocked by the angiotensin II type 1 receptor blocker losartan, and by

79 one or combined with telmisartan, a specific angiotensin II type 1 receptor blocker.

80 Although angiotensin II type 1 receptor blockers have emerged as

81 Angiotensin II type 1 receptor blockers have favourable

82 at angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers, or aldosterone

83 of angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers, or both as firs

84 termined the conformation of the ECL2 of the angiotensin II type 1 receptor by reporter-cysteine acce

85 s a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor; it antagonizes canonical

86 ide, TRV120027, a novel beta-arrestin biased angiotensin II type 1 receptor ligand, preserved furosem

87 of polymorphisms of AGTR1, the gene encoding angiotensin-II type 1 receptor of RAS, on longitudinal h

88 VLM of normotensive rats is not mediated via angiotensin II type 1 receptor, oxytocin, ionotropic glu

89 Our data demonstrate that angiotensin II type 1 receptors promote ADAM17-mediated

90 1), advanced glycation end product (AGE) and angiotensin II type 1 receptors (receptor for advanced g

91 Inhibition of the angiotensin II type 1 receptor reduced renal creatinine

92 ced by angiotensin II (AngII) binding to the angiotensin II type 1 receptor resemble those evoked by

93 st activation of several GPCRs including the angiotensin II type 1 receptor specifically augmented Gb

94 system and ADAM17, we generated mice lacking angiotensin II type 1 receptors specifically on neurons.

95 nsin system occur through stimulation of the angiotensin II type 1 receptor, the focus of this review

96 ecreases of RV expression of chymase and the angiotensin II type 1 receptor, while RV angiotensinogen